$ Value
$0
Shares
12,925
Price
$0
Filed
Nov 26
Insider
Name
Trout Harry R. III
Title
See Remarks
CIK
0002085123
Roles
Transaction Details
Transaction Date
2025-11-25
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
12,925
Footnotes
Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 1, 2026 and in substantially equal annual installments over the next three anniversaries thereafter. | Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025).
Filing Info
Trout Harry R. III's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2025-12-05 | ENTA | ▼ | $8K |
| 2025-12-02 | ENTA | ▼ | $5K |
| 2025-12-01 | ENTA | F | $1K |
| 2025-11-25 | ENTA | A | $0 |
| 2025-11-25 | ENTA | A | $0 |
Other Insiders at ENTA (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| CARTER BRUCE L A | — | — | 2026-03-11 |
| FOLETTA MARK G | — | — | 2026-03-11 |
| Russell Lesley | — | — | 2026-03-11 |
| Peterson Kristine | — | — | 2026-03-11 |
|
Luly Jay R.
President and CEO
|
— | — | 2026-02-12 |
|
Or Yat Sun
Chief Scientific Officer
|
— | — | 2026-02-12 |
| Vance Terry | — | — | 2026-03-11 |
| Hata Yujiro S | — | — | 2026-03-11 |
|
Kowalsky Matthew Paul
Chief Legal Officer
|
— | — | 2026-02-12 |
|
Kieffer Tara Lynn
Chief Product Strategy Officer
|
— | — | 2026-02-12 |
|
Luu Brendan
Chief Business Officer
|
— | — | 2026-02-12 |
|
Rottinghaus Scott T.
Chief Medical Officer
|
— | — | 2026-02-12 |